Publication date: Dec 27, 2024
Between April-October 2021, the New York City (NYC) Health Department conducted a serosurvey to assess prevalence of SARS-CoV-2 antibodies in NYC adults as part of continued COVID-19 surveillance efforts. Whole blood specimens were collected from 1,035 adult NYC residents recruited from an annual population-based health surveillance survey. Specimens were tested for the presence of anti-SARS-CoV-2 spike protein (anti-spike) and anti-SARS-CoV-2 nucleocapsid protein (anti-nucleocapsid) antibodies. 91. 6% (95% CI: 87. 45-94. 50) had anti-spike antibodies and 30. 4% (95% CI: 24. 78-36. 7) had anti-nucleocapsid antibodies. Almost all participants with anti-spike antibodies produced antibodies capable of neutralizing SARS-CoV-2. Overall, anti-spike positivity was lowest (85. 9% [95% CI: 74. 01-92. 85) in Hispanic and Latino New York City residents. Conversely, anti-nucleocapsid seropositivity was highest in Black New York City residents (39. 9%, 95% CI: 25. 5-49. 3). Continued disparities persist in SARS-CoV-2 seropositivity regarding ethnic and sociodemographic factors. SARS-CoV-2 seropositivity was high in 2021 in NYC, with evidence of continued inequities associated with seroprevalence.
| Concepts | Keywords |
|---|---|
| Antibodies | health equity |
| April | SARS-CoV-2 |
| Hispanic | seroprevalence |
| Nyc | surveillance |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |